Impact of a vincristine dose cap on the incidence of neuropathies with DA-EPOCH-R for the treatment of aggressive lymphomas

References

• Orazi A, Nielsen O, Go RS, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3460–3467.
   PubMed Web of Science ®Google Scholar
• Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354–2361.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99(8):2685–2693.
   PubMed Web of Science ®Google Scholar
• Gutierrez M, Chabner BA, Pearson D, et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol. 2000;18(21):3633–3642.
   PubMed Web of Science ®Google Scholar
• Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982;96(2):133–139.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med. 2013;369(20):1915–1925.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368(15):1408–1416.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Lee JY, Kaplan LD, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010;115(15):3008–3016.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Wilson WH, Jung S-H, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790–1799.
   PubMed Web of Science ®Google Scholar
• Desai ZR, Van den Berg HW, Bridges JM, et al. Can severe vincristine neurotoxicity be prevented? Cancer Chemother Pharmacol. 1982;8(2):211–214.
   PubMed Web of Science ®Google Scholar
• Silverman JA, Deitcher SR. Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother Pharmacol. 2013;71(3):555–564.
   PubMed Web of Science ®Google Scholar
• Carbone P, Bono V, Frei IIE, et al. Clinical studies with vincristine. Blood. 1963;21(5):640–647.
   PubMed Web of Science ®Google Scholar
• Luce J, Gamble J, Wilson H, et al. Combined cyclophosphamide, vincristine, and prednisone therapy of malignant lymphoma. Cancer. 1971;28(2):306–317.
   PubMed Web of Science ®Google Scholar
• Verstappen CCP, Koeppen S, Heimans JJ, et al. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology. 2005;64(6):1076–1077.
   PubMed Web of Science ®Google Scholar
• Haim N, Epelbaum R, Ben‐Shahar M, et al. Full dose vincristine (without 2‐mg dose limit) in the treatment of lymphomas. Cancer. 1994;73(10):2515–2519.
   PubMed Web of Science ®Google Scholar
• Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2012;30(13):1553–1561.
   PubMed Web of Science ®Google Scholar
• Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE) v5.0. National Cancer Institute: Division of Cancer Treatment & Diagnosis; 2018 [accessed 2018 Mar 3]. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50
   Google Scholar
• Yalowich JC. Effects of microtubule inhibitors on etoposide accumulation and DNA damage in human K562 cells in vitro. Cancer Res. 1987;47(4):1010–1015.
   PubMed Web of Science ®Google Scholar
• Ackland SP, Ratain MJ, Vogelzang NJ, et al. Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin. Clin Pharmacol Ther. 1989;45(4):340–347.
   PubMed Web of Science ®Google Scholar
• Lai G‐M, Chen Y‐N, Mickley LA, et al. P‐glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer. 1991;49(5):696–703.
   PubMed Web of Science ®Google Scholar
• Moser EC, Noordijk EM, Carde P, et al. Late non-neoplastic events in patients with aggressive non-Hodgkin’s lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials. Clin Lymphoma Myeloma. 2005;6(2):122–130.
   PubMedGoogle Scholar
• Oerlemans S, Issa DE, van den Broek EC, et al. Health-related quality of life and persistent symptoms in relation to (R-)CHOP14, (R-)CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: results of the population-based PHAROS-registry. Ann Hematol. 2014;93(10):1705–1715.
   PubMed Web of Science ®Google Scholar
• Kim BJ, Park HR, Roh HJ, et al. Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma. Qual Life Res. 2010;19(8):1097–1103.
   PubMed Web of Science ®Google Scholar
• McGrath R, Erlandson KM, Vincent BM, et al. Decreased handgrip strength is associated with impairments in each autonomous living task for aging adults in the United States. J Frailty Aging. 2019;8(3):141–145.
   PubMed Web of Science ®Google Scholar
• Arenas Jiménez MD, Navarro García M, Serrano Reina E, et al. Disability in instrumental activities of daily living in hemodialysis patients: Influence on quality of life related to health. Nefrologia. 2019;39(5):531–538.
   PubMedGoogle Scholar